MicroRNA-10a expression in FAB different subtype of acute myeloid leukemia and its relationship with drug resistance.
- Author:
Yong-Jin ZHI
1
;
Feng ZHI
2
;
Rong WANG
2
;
Lian XUE
2
;
Wei-Ying GU
1
;
Biao WANG
1
;
Wei-Min DONG
1
;
Hai-Qian LI
1
;
Yun LING
1
;
Guo-Qiang QIU
1
;
Zhi-Lin WANG
1
;
Xiang-Shan CAO
1
;
Yan LIU
3
Author Information
- Publication Type:Journal Article
- MeSH: Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid, Acute; MicroRNAs
- From: Journal of Experimental Hematology 2015;23(1):29-33
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVEThis study was to investigate the expression of miR-10a in the different FAB subtype of acute myeloid leukemia (AML) and its relationship with drug resistance.
METHODSForty de novo patients with AML, 16 patients with non-malignant hematologic disease and three AML cell lines HL-60, U937 and HL-60/ADR were enrolled in this study, the MiR-10a expression in bone marrow mononuclear cells of above-mentioned patients and 3 AML cell lines was detected by TaqMan RT-PCR. The correlation of miR-10a with clinicopathological factors of AML patients was analyzed.
RESULTSThe miR-10a expression level in HL-60 cell line was higher than that in U937 cell line (P = 0.039). And its expression level in de novo AML patients was higher than that in patients with non-malignant hematologic disease (P < 0.01). FAB-AML-M3 patients exhibited higher expression of miR-10a than that in M1, M2 and M4 (P < 0.05); HL-60/ADR cell line showed higher miR-10a expression than that in HL-60 cell line (P < 0.01) . Except M3, the patients without CR (non-CR) after the first cycle of chemotherapy showed a higher level of miR-10a as compared with CR patients (P < 0.01).
CONCLUSIONThe high expression of miR-10a may be closely related to over-proliferation of promyelocyte and drug resistance of acute myeloid leukemia cells, except M3.
